title: What place for lisdexamfetamine in children and adolescents with ADHD?
abstract: Attention deficit hyperactivity disorder (ADHD) is the commonest behavioural disorder in the UK, affecting 2-5% of school-aged children and young people.(1) Guidelines from the National Institute for Health and Care Excellence (NICE) state that medication is not indicated as first-line treatment for school-age children and young people with ADHD, but should be reserved for those with severe symptoms and impairment, or those with moderate levels of impairment who have refused non-drug interventions, or those whose symptoms have not responded sufficiently to parent-training/education programmes or group psychological treatment.(2) Current drug options include methylphenidate (first-line), atomoxetine (first- or second-line) or dexamfetamine (second- or third-line).(2) Lisdexamfetamine (Elvanse-Shire Pharmaceuticals) is a prodrug of dexamfetamine, licensed as part of a comprehensive treatment programme for ADHD in children aged 6 years and over when response to previous methylphenidate treatment is considered clinically inadequate.(3,4) Here we review the place of lisdexamfetamine in the management of ADHD in children and adolescents.
mesh_terms: D000293:Adolescent; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology; D000697:Central Nervous System Stimulants / Q000627:therapeutic use*; D002648:Child; D003913:Dextroamphetamine / Q000627:therapeutic use*; D006801:Humans; D000069478:Lisdexamfetamine Dimesylate; D017410:Practice Guidelines as Topic; D012720:Severity of Illness Index; D006113:United Kingdom / Q000453:epidemiology
chemical_list: D000697:Central Nervous System Stimulants; D000069478:Lisdexamfetamine Dimesylate; D003913:Dextroamphetamine